A share price of Intellia Therapeutics Inc [NTLA] is currently trading at $4450000.0, up 5902867%. An important factor to consider is whether the stock is rising or falling in short-term value. The NTLA shares have gain 10.18% over the last week, with a monthly amount drifted -4.86%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Intellia Therapeutics Inc [NASDAQ: NTLA] stock has seen the most recent analyst activity on April 21, 2025, when Wolfe Research upgraded its rating to a Outperform but kept the price target unchanged to $21 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on March 05, 2025, and set its price target to $30. On February 28, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $13 on the stock. Goldman downgraded its rating to a Sell but stick to its price target of $9 on February 28, 2025. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $11 on January 27, 2025. Goldman downgraded its rating to Neutral for this stock on February 23, 2024, and downed its price target to $32. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
Intellia Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $5.90 and $28.18. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Intellia Therapeutics Inc [NASDAQ: NTLA] shares were valued at $4450000.0 at the most recent close of the market. An investor can expect a potential drop of -100.0% based on the average NTLA price forecast.
Analyzing the NTLA fundamentals
Trailing Twelve Months sales for Intellia Therapeutics Inc [NASDAQ:NTLA] were 45.57M which represents -42.54% decline. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -11.87%, Pretax Profit Margin comes in at -11.54%, and Net Profit Margin reading is -11.54%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.59 and Total Capital is -0.62. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Intellia Therapeutics Inc [NASDAQ:NTLA] is 4.90. On the other hand, the Quick Ratio is 4.90, and the Cash Ratio is 1.13. Considering the valuation of this stock, the price to sales ratio is 20.91, the price to book ratio is 1.22.
Transactions by insiders
Recent insider trading involved Bhanji Muna, Director, that happened on Apr 29 ’25 when 265.0 shares were sold. EVP, Chief Technical Officer, Clark Eliana completed a deal on Mar 04 ’25 to sell 679.0 shares. Meanwhile, EVP, General Counsel BASTA JAMES sold 2572.0 shares on Mar 04 ’25.
